Login
Israel-Hamas Conflict
Independence Day
Floods
World Cup
Natural Disasters
Social Media
South America
Real Madrid
Artificial Intelligence
Soccer
Donald Trump
BRICS
Parade
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Beacon Therapeutics exercises option to license Abeona Therapeutics’ AAV204 capsid

Summary by ophthalmologytimes.com
AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
ophthalmologytimes.comophthalmologytimes.com

Beacon Therapeutics exercises option to license Abeona Therapeutics’ AAV204 capsid

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ophthalmologytimes.com broke the news in on Thursday, July 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Chapel Hill, North Carolina icon

Chapel Hill, North Carolina

News
For You
SearchBlindspotLocal